You can download the publications of the team here:

Year	Title	PDF
2019	Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance
2018	BrdU incorporation in multiparameter flow cytometry : A new cell cycle assessment approach in multiple myeloma
2018	PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs
2018	DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells
2017	Combined inhibition of two bad prognosis genes: Chk1 and Wee1 as a new therapeutic strategy for Multiple Myeloma [Abstract]
2017	Combined inhibition of two bad prognosis genes: Chk1 and Wee1 as a new therapeutic strategy for Multiple Myeloma [Poster]
2017	CD24, CD27, CD36 and CD302 gene expression for outcome prediction in patients with multiple myeloma
2017	An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy
2017	Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell
2017	RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma
2017	Automated and Simplified Identification of Normal and Abnormal Plasma Cells in Multiple Myeloma by Flow Cytometry
2017	Hypoxia favors the generation of human plasma cells
2016	Differential effects of lenalidomide during plasma cell differentiation
2016	Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy
2016	Chetomin, targeting HIF-1a/p300 complex, exhibits antitumour activity in multiple myeloma
2015	GenomicScape : AnEasy-to-Use Web Tool for Gene Expression Data Analysis. Application to Investigate the Molecular Events in the Differentiation of B Cells into Plasma Cells
2014	DNA repair in diffuse large B-cell lymphoma: a molecular portrait
2013	Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma
2013	Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
2012	Gene expression-based risk score in diffuse large B-cell lymphoma
2012	Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients
2012	Development of gene expression based score to predict sensitivity of multiple myeloma cells to DNA methylation
2011	Characterization of a Transitional Preplasmablast Population in the Process of Human B Cell to Plasma Cell Differentiation
2011	A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines
2009	An in vitro model of differentiation of memory B cells into plasma blasts and plasma cells including detailed phenotypic and molecular characterization

The Patents of the Team:

Year	Title
2017	Residual disease detection in multiple myeloma. Requirand G, Klein B, Reme T, Moreaux J and al. PCT/EP2017/062307 ; WO2017198879A1. Patent FR1654514
2017	Methods using blm as a marker of multiple myeloma. Moreaux J, Sapede E, Pasero P, Constantinou A. PCT/EP2017/064020; WO2017211983A1. Patent EP16305682,
2017	Methods and pharmaceutical compositions for the treatment of multiple myeloma. Moreaux J, Julien E, Izard F, Grimaud C, Herviou L. PCT/EP2017/053435; WO2017140743A1 Patent EP16305176
2016	Method for the in vitro prognosis of individuals having Multiple Myeloma and method for the treatment thereof. Cavalli G, Kassambara A, Herviou L. Moreaux J. Patent EP16306436.3,
2016	Method for the prognosis of multiple myeloma. Aleterre E, Moreaux J. Patent EP16305651
2014	Methods for predicting response to DNA repair pathway inhibitors in diffuse large B-cell lymphoma. Moreaux J, Bret C, Cartron G, Constantinou A, Pasero P. PCT/EP2015/067174 Patent EP14306201
2014	Method for predicting DNMTi/HDACi combination treatment response in Multiple Myeloma. Moreaux J, Klein B. EP2015/055992 Patent EP14305404,
2012	Method for predicting HDACi treatment response in Multiple Myeloma. Moreaux J, Klein B. WO2014056928 Patent EP12306225.9,
2012	Method for predicting multiple myeloma treatment response. Moreaux J, Klein B. WO2014044848 Patent EP12306141.8,
2010	Classification, diagnosis and prognosis of multiple myeloma. Moreaux J, Pellat-Deceunynck C, Klein B. WO2012022634 Patent n° 10305892

By admin on November 5, 2018   /   Publications